The Europe Autoinjectors Market is expected to witness market growth of 17.1% CAGR during the forecast period (2020-2026).
Auto-injectors have numerous advantages like they lessen phobia and anxiety related to needles, decrease chances of a needle stuck incidences, keep the consistency of dose precision, and also help with better efficiency, which, in turn, support growth. Drug delivery by using an auto-injector is more controlled than manual injection.
The administration site of any drug is chosen on the basis of the nature of the drug; however, it is usually administered intramuscularly. Autoinjectors, if compared to syringes, are less painful, thus demand is increasing. Though, the availability of substitutes like oral tablets may obstruct growth.
In a reasonably short time period, the market for self-injection devices has full-fledged into a conspicuous and promising segment in the pharmaceutical industry. Autoinjectors are one such device that has witnessed amplified adoption among patients, particularly for the treatment of emergency situations like anaphylactic shocks. As per the developers, these devices are quite easier to use as compared to parenteral drug delivery systems and have incorporated needle-safety features. It has been proved that the autoinjectors have resolved a number of issues faced by patients such as injection-related tolerability.
Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.
Scope of the Study
Market Segments covered in the Report:
By Type
By Application
By End Use
By Country
Companies Profiled
Unique Offerings from the Publisher
Auto-injectors have numerous advantages like they lessen phobia and anxiety related to needles, decrease chances of a needle stuck incidences, keep the consistency of dose precision, and also help with better efficiency, which, in turn, support growth. Drug delivery by using an auto-injector is more controlled than manual injection.
The administration site of any drug is chosen on the basis of the nature of the drug; however, it is usually administered intramuscularly. Autoinjectors, if compared to syringes, are less painful, thus demand is increasing. Though, the availability of substitutes like oral tablets may obstruct growth.
In a reasonably short time period, the market for self-injection devices has full-fledged into a conspicuous and promising segment in the pharmaceutical industry. Autoinjectors are one such device that has witnessed amplified adoption among patients, particularly for the treatment of emergency situations like anaphylactic shocks. As per the developers, these devices are quite easier to use as compared to parenteral drug delivery systems and have incorporated needle-safety features. It has been proved that the autoinjectors have resolved a number of issues faced by patients such as injection-related tolerability.
Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.
Scope of the Study
Market Segments covered in the Report:
By Type
- Disposable autoinjectors
- Reusable autoinjectors
By Application
- Anaphylaxis
- Rheumatoid Arthritis
- Multiple Sclerosis
- Other Applications
By End Use
- Hospitals & Clinics
- Home care settings
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- Eli Lilly and Company
- GlaxoSmithKline PLC (GSK)
- Merck Group
- Sanofi S.A.
- Becton, Dickinson and Company
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- Ypsomed AG
- AbbVie, Inc.
- Biogen, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Autoinjectors Market by Type
Chapter 5. Europe Autoinjectors Market by Application
Chapter 6. Europe Autoinjectors Market by End Use
Chapter 7. Europe Autoinjectors Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Eli Lilly and Company
- GlaxoSmithKline PLC (GSK)
- Merck Group
- Sanofi S.A.
- Becton, Dickinson and Company
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- Ypsomed AG
- AbbVie, Inc.
- Biogen, Inc.
Methodology
LOADING...
